Search

The harm associated with imaging abnormalities related to lung cancer screening (LCS) is not well documented, especially outside the clinical trial and academic setting. What is the frequency of invasive procedures and complications associated with a community based LCS program, including procedures for false-positive and benign, but clinically important, incidental findings? We performed a single-center retrospective study of an LCS program at a nonuniversity teaching hospital from 2016 through 2019 to identify invasive procedures prompted by LCS results, including their indication and complications. Among 2,003 LCS participants, 58 patients (2.9%) received a diagnosis of lung cancer and 71 patients (3.5%) received a diagnosis of any malignancy. Invasive procedures were performed 160 times in 103 participants (5.1%), including 1.7% of those without malignancy. Eight invasive procedures (0.4% of participants), including four surgeries (12% of diagnostic lung resections), were performed for false-positive lung nodules. Only 1% of Lung Imaging Reporting and Data System category 4A nodules that proved benign were subject to an invasive procedure. Among those without malignancy, an invasive procedure was performed in eight participants for extrapulmonary false-positive findings (0.4%) and in 19 participants (0.9%) to evaluate incidental findings considered benign but clinically important. Procedures for the latter indication resulted in treatment, change in management, or diagnosis in 79% of individuals. Invasive procedures in those without malignancy resulted in three complications (0.15%). Seventy nonsurgical procedures (6% complication rate) and 48 thoracic surgeries (4% major complication rate) were performed in those with malignancy. The use of invasive procedures to resolve false-positive findings was uncommon in the clinical practice of a nonuniversity LCS program that adhered to a nodule management algorithm and used a multidisciplinary approach. Incidental findings considered benign but clinically important resulted in invasive procedure rates that were similar to those for false-positive findings and frequently had clinical value. [ABSTRACT FROM AUTHOR]

Background: In addition to the diameters of pulmonary nodules, the number and morphology of blood vessels in pure ground-glass nodules (pGGNs) were closely related to the occurrence of lung cancer. Moreover, the benign and malignant signs of nodules were also valuable for the identification of nodules. Based on these two points, we tried to revise Lung-RADS 2022 and proposed our Modified Lung-RADS. The aim of the study was to verify the diagnostic performance of Modified Lung-RADS for pulmonary solid nodules (SNs) and pure ground-glass nodules (pGGNs) in patients with previous malignancies. Methods: The chest CT and clinical data of patients with prior cancer who underwent pulmonary nodulectomies from 1 January 2018 to 30 November 2021 were enrolled according to inclusion and exclusion criteria. A total of 240 patients with 293 pulmonary nodules were included in this study. In contrast with the original version, the risk classification of pGGNs based on the GGN–vascular relationships (GVRs), and the SNs without burrs and with benign signs, could be downgraded to category 2. The sensitivity, specificity, and agreement rate of the original Lung-RADS 2022 and Modified Lung-RADS for pGGNs and SNs were calculated and compared. Results: Compared with the original version, the sensitivity and agreement rate of the Modified version for pGGNs increased from 0 and 23.33% to 97.10% and 92.22%, respectively, while the specificity decreased from 100% to 76.19%. As regards SNs, the specificity and agreement rate of the Modified version increased from 44.44% to 75.00% (p < 0.05) and 88.67% to 94.09% (p = 0.052), respectively, while the sensitivity was unchanged (98.20%). Conclusions: In general, the diagnostic efficiency of Modified Lung-RADS was superior to that of the original version, and Modified Lung-RADS could be a preliminary attempt to improve Lung-RADS 2022. [ABSTRACT FROM AUTHOR]

Abstract Background Lung assessment is highly recommended in the management of oncology patients as it is the commonest affected site in metastatic dissemination. The low-dose CT with nodule reporting system based on Lung Reporting and Data System (lung-RADS) is a promising non-invasive tool for the characterization of incidentally detected pulmonary nodules. The authors aimed to assess the accuracy of the “lung-RADS” classification system as a non-invasive tool for the characterization of any newly developed pulmonary nodules among oncology patients. Ethics committee approval and informed written consent were obtained from the studied patients. A non-contrast LDCT study was performed on all patients with a nodule reporting system based on the lung-RADS classification system applied for evaluation of each detected pulmonary nodule. Diagnoses were established using the help of either histopathology or follow-up clinical results as a gold standard. Results In this prospective study, we enrolled 187 known malignancy patients with 200 suspicious newly developed pulmonary nodules. Their mean patient age was 48.4 ± 9.7 years. The studied 200 pulmonary nodular lesions were categorized using a nodule reporting system based on the lung-RADS into 6 sub-groups with 122 lesions found to be malignant and 78 lesions were of benign etiology, which showed a high sensitivity of 92.08%, specificity of 78.79%, and accuracy of 85.50% with 81.58% positive predictive value and 90.70% negative predictive value in the diagnosis of pulmonary nodules in cancer patients. Conclusion Low-density CT with a nodule reporting system based on the lung-RADS classification system was found to be an accurate non-invasive tool to characterize and to risk stratify pulmonary nodules in oncology patients.

Background: In addition to the diameters of pulmonary nodules, the number and morphology of blood vessels in pure ground-glass nodules (pGGNs) were closely related to the occurrence of lung cancer. Moreover, the benign and malignant signs of nodules were also valuable for the identification of nodules. Based on these two points, we tried to revise Lung-RADS 2022 and proposed our Modified Lung-RADS. The aim of the study was to verify the diagnostic performance of Modified Lung-RADS for pulmonary solid nodules (SNs) and pure ground-glass nodules (pGGNs) in patients with previous malignancies. Methods: The chest CT and clinical data of patients with prior cancer who underwent pulmonary nodulectomies from 1 January 2018 to 30 November 2021 were enrolled according to inclusion and exclusion criteria. A total of 240 patients with 293 pulmonary nodules were included in this study. In contrast with the original version, the risk classification of pGGNs based on the GGN–vascular relationships (GVRs), and the SNs without burrs and with benign signs, could be downgraded to category 2. The sensitivity, specificity, and agreement rate of the original Lung-RADS 2022 and Modified Lung-RADS for pGGNs and SNs were calculated and compared. Results: Compared with the original version, the sensitivity and agreement rate of the Modified version for pGGNs increased from 0 and 23.33% to 97.10% and 92.22%, respectively, while the specificity decreased from 100% to 76.19%. As regards SNs, the specificity and agreement rate of the Modified version increased from 44.44% to 75.00% (p < 0.05) and 88.67% to 94.09% (p = 0.052), respectively, while the sensitivity was unchanged (98.20%). Conclusions: In general, the diagnostic efficiency of Modified Lung-RADS was superior to that of the original version, and Modified Lung-RADS could be a preliminary attempt to improve Lung-RADS 2022.

Lung cancer screening is slowly but steadily entering the realm of preventive health maintenance. Standardization of reporting of positive findings identified on screening low-dose CT (LDCT) scans, specifically lung nodules, is a key element of high-quality lung cancer screening. The American College of Radiology developed the Lung CT Screening Reporting and Data System (Lung-RADS) system for this purpose. In addition to detailed categorization of lung nodules, Lung-RADS identifies category S for other incidental findings identified on screening LDCT scans. In contrast to the highly structured reporting for nodules, category S findings are reported at the discretion of individual readers, with the potential for high variability of reporting. Incidental findings on lung cancer screening studies are common, may trigger unwarranted evaluation with potential harm and cost, and may precipitate patient distress. In response to these concerns, our multidisciplinary lung cancer screening program developed a structured system for standardized reporting of category S findings based on recommendations of the American College of Radiology and relevant specialty societies. [ABSTRACT FROM AUTHOR]

Background: Lung assessment is highly recommended in the management of oncology patients as it is the commonest affected site in metastatic dissemination. The low-dose CT with nodule reporting system based on Lung Reporting and Data System (lung-RADS) is a promising non-invasive tool for the characterization of incidentally detected pulmonary nodules. The authors aimed to assess the accuracy of the "lung-RADS" classification system as a non-invasive tool for the characterization of any newly developed pulmonary nodules among oncology patients. Ethics committee approval and informed written consent were obtained from the studied patients. A non-contrast LDCT study was performed on all patients with a nodule reporting system based on the lung-RADS classification system applied for evaluation of each detected pulmonary nodule. Diagnoses were established using the help of either histopathology or follow-up clinical results as a gold standard. Results: In this prospective study, we enrolled 187 known malignancy patients with 200 suspicious newly developed pulmonary nodules. Their mean patient age was 48.4 ± 9.7 years. The studied 200 pulmonary nodular lesions were categorized using a nodule reporting system based on the lung-RADS into 6 sub-groups with 122 lesions found to be malignant and 78 lesions were of benign etiology, which showed a high sensitivity of 92.08%, specificity of 78.79%, and accuracy of 85.50% with 81.58% positive predictive value and 90.70% negative predictive value in the diagnosis of pulmonary nodules in cancer patients. Conclusion: Low-density CT with a nodule reporting system based on the lung-RADS classification system was found to be an accurate non-invasive tool to characterize and to risk stratify pulmonary nodules in oncology patients. [ABSTRACT FROM AUTHOR]

• Refining of estimated malignancy rates across Lung-RADS 4 categories is necessary. • The probability of lung cancer increases from category 4A to 4X. • CT imaging features may help differentiate benign from malignant nodules. • Imaging features can help formulate risk prediction models. To assess the prevalence of lung cancer in Lung-RADS category 4 patients, and to elucidate if clinical or imaging features help differentiate benign lesions from lung cancer. A retrospective review of lung cancer screening (LCS) studies at a single university screening program between January 2018 and December 2021 identified all patients with Lung-RADS category 4 lesions. Patient demographics, symptoms within the prior 6 months, and imaging features were recorded. During the defined period, 4819 baseline and annual LCS exams were performed; 7.6 % (n = 368) of exams had category 4 nodules and 59 (1.2 %) patients had biopsy-proven lung cancer. Distribution of Lung-RADS category 4 lesions and lung cancer diagnosis were as follows: 4A − 223 nodules, 6.3 % malignant; 4B − 114 nodules, 20.2 % malignant; and 4X − 31 nodules, 71.0 % malignant. Symptoms were reported in 9.0 % (n = 20) of category 4A (2 were malignant), 15.8 % (n = 18) category 4B (1 was malignant) and 22.6 % (n = 7) category 4X (5 were malignant). Imaging features associated with malignancy included endobronchial obstruction with distal atelectasis, pleural tethering, irregular shape, cavitation, and heterogeneous cystic appearance. Twenty-four nodules increased in size, however, only 7 were biopsy proven. Relative to the risk seen with 4A disease, multivariable logistic analyses showed that the odds of a malignancy increased significantly by 3.8 fold (95 % CI: 1.9, 7.9) and 39.2 fold (95 % CI: 14.9, 103.0) with 4B and 4X disease, respectively (p < 0.0001). A separate analysis involving only category 4A and 4B patients jointly showed that disease category (OR = 3.0; 95 % CI: 1.5, 6.4) and additional imaging features (OR = 3.2; 95 % CI: 1.4, 7.0) were significant predictors of malignancy. The presence of clinical symptoms was not statistically associated with lung cancer. Lung-RADS 4 nodules were found in 7.6% of LCS examinations and 16% of these nodules were lung cancer. The probability of lung cancer increases from category 4A to 4X, and imaging features may help differentiate benign from malignant nodules in this LCS category. [ABSTRACT FROM AUTHOR]